Need professional-grade analysis? Visit stockanalysis.com
$782.18M
N/A
N/A
N/A
Theravance Biopharma Inc (TBPH) trades on United States in USD. The company is classified in the Healthcare sector under the Pharmaceutical Preparations industry. The stock currently trades at $17.23, up 2.68% from the previous close.
Over the past year, TBPH has traded between a low of $8.41 and a high of $20.74. The stock has gained 85.1% over this period. It is currently 16.9% below its 52-week high.
Theravance Biopharma Inc has a market capitalization of $782.18M.
Theravance Biopharma, Inc., a biopharmaceutical company, develops and commercializes medicines in the United States. It offers YUPELRI, an once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD); and Ampreloxetine an investigational, once-daily norepinephrine reuptake inhibitor, Which is in Phase 3 clinical trials for symptomatic neurogenic orthostatic hypotension (nOH) in patients with Multiple System Atrophy (MSA). It has a strategic collaboration agreement with Viatris Inc. for the development and commercialization of revefenacin, including YUPELRI inhalation solution. Theravance Biopharma, Inc. was incorporated in 2013 and is based in South San Francisco, California.
Side-by-side comparison against top Healthcare peers.